RATIONALE: Hereditary angioedema (HAE) with normal C1 inhibitor (nlC1-INH) is a rare condition, with clinical features similar to those of HAE with C1-INH deficit. Hormones have a special role as triggering factor. There is no biomarker for diagnosis, requiring a compatible clinical and familial history and/or identification of associated mutation (Factor 12, Angiopoietin 1 and Plasminogen). METHODS: We evaluated 295 patients (242 F: 53 M) out of 101 families with confirmed diagnosis of HAE nlC1-INH from 16 reference centers in Brazil. RESULTS: 72.9% (215/295) were symptomatic (194F:21M) and 27.1% (80/295) asymptomatic with age range 3 -91 years (median: 36). Genetic evaluation showed: F12 mutation 178/245 (72.6%); angiopoietin1 in 4/245 and 63/245 had unknown mutation. Symptoms initiated between 2 -68 years old (median518). Main triggering factors: hormones 68.3%; stress 59.6%; trauma 47.6%; dental therapy 13.9%; unknown 13% and others 27%. Edema occurred in: face 84.6%; abdomen 75.5%; extremities 61.1%; laryngeal 36.1%; tongue 23.1% and others. Three patients died due to HAE. One third of the patients improved after contraceptive withdrawal only; 21.3% (36) treated on demand; continuous prophylaxis was used in 68.6% and 18.3% for surgical procedures; 22.5% increased doses of prophylactic medications during the attacks. Main prophylactic drug was tranexamic acid (n545). CONCLUSIONS: F12 mutation was present in a high number of our patients in comparison with other reports. Symptoms persisted in the majority of patients although estrogen therapy was interrupted. Plasmin inhibitor was effective in HAE nlC1-INH.
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Prodromal Symptoms In Bradykinin Vs. Histamine-Mediated Angioedema Amie H. Nguyen, MD, and Marc A. Riedl, MD, MS; University of California, San Diego, La Jolla, CA. RATIONALE: Prodromal symptoms (PS) in bradykinin-mediated angioedema (B) have been well described however data regarding prodromes in histamine-mediated angioedema (H) is lacking. We assessed the prevalence, types and reliability of prodromes in spontaneous histaminergic angioedema. METHODS: 73 patients (men and non-pregnant women between the ages of 18-70) receiving care at the US HAEA Angioedema Center were recruited for an anonymous 11 question survey. 30 patients had spontaneous histamine-mediated angioedema and 43 patients had either of the following bradykinin-mediated forms of angioedema: hereditary angioedema (HAE) with C1 inhibitor deficiency/dysfunction or HAE with normal C1 inhibitor. Frequencies were summarized and statistical analyses were calculated using Fisher's exact, Mann-Whitney U or Independent t-tests. RESULTS: 95.3% of B and 66.7% of H patients reported PS prior to their last angioedema (AE) attack (p50.002) and 97.6% of B and 80% of H patients reported PS associated with any previous AE attacks. The average number of PS before the last AE attack was 6.17 in B and 2.35 in H (p<0.005). The most frequent PS in B was upset stomach/nausea (63.4%) and in H was cutaneous numbness/tingling (40%). 71% of B and 63% of H patients reported being able to predict AE attacks based on PS at least 75% of the time. PS were followed by AE attacks at least 75% of the time in 80.5% of B and 45% of H patients. CONCLUSIONS: Prodomal symptoms occur in a majority of patients with histamine-mediated angioedema though appear more prevalent and predictive in bradykinin-mediated conditions. Shire, Lexington, MA, 2 Certara Strategic Consulting, Montreal, Canada. RATIONALE: Lanadelumab is a plasma kallikrein (pKal) inhibitor (monoclonal antibody) indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients > _12 years of age. 2-chain highmolecular weight kininogen (cHMWK), a product of active pKal, has been evaluated as a potential biomarker for the effect of lanadelumab. Exposureresponse (ER) analyses were performed to support dosing of lanadelumab in patients with HAE. METHODS: Data from 125 patients in the HELP Study treated with placebo, lanadelumab 150 mg Q4W, 300 mg Q4W, or 300 mg Q2W for 6 months were analyzed. The longitudinal ER model included a logarithm of the Poisson distribution to assess the impact of treatment duration and drug exposure on the number of HAE attacks/month. Time to first attack was assessed using Kaplan-Meier analyses and Cox proportional hazard modeling with steady state exposure and cHMWK suppression as continuous parameters. RESULTS: The relationship between lanadelumab and the number of attacks/month was described using a placebo model (linear time-response model) and an E max -type model for drug effect (ER model). The ER was very steep, with plateauing of effect observed at Month 5-6. An E max of -3.74 HAE attacks/month was estimated. Higher exposure to lanadelumab and suppression of cHMWK following administration of lanadelumab 300 mg Q2W were associated with a significant prolongation in the time to first attack. CONCLUSIONS: Exposure-response analyses suggest that longer chronic treatments with the 300 mg Q2W regimen were associated with further improvement in HAE control (number of HAE attacks/month) and a significant delay in time to first attack.
